

**Annual Report
Division of Gastroenterology
Department of Medicine - Jewish General Hospital
January 1 - December 31, 2014**

SUMMARY:

Introduction

There were no new significant developments over the 2014 calendar year other than the continued development of the IBD Rapid Access Clinic which has proven to be extremely successful with patients and staff.

No new faculty has been hired. Efforts have been made to try to recruit Dr. P. De Sousa for interventional endoscopy but we have not succeeded due to a lack of a PREM.

Clinical Activities

Office visits

Dr. A. Cohen	Monday to Friday	8-4 pm
Dr. G. Friedman	Monday to Friday	8-4 pm 18 902visits/year
Dr. A. Szilagyi	Monday to Friday	8-4 pm
Dr. N. Hilzenrat	Monday to Friday	8-4 pm
Dr. P. Galiatsatos	Monday to Friday	8-4 pm

Endoscopy laboratory: Endoscopy volume for 12 months was 9950 in total. This includes 5583 out patients and 4367 in patients.

Monday to Friday	8-4 pm	9950 procedures/year
------------------	--------	----------------------

Cholangiopancreatography (ERCP)

Mondays and Thursdays	1-4 pm	243 procedures/year (included in Endoscopy)
-----------------------	--------	--

Inflammatory Bowel Disease Clinics

Monday to Friday	8-12 pm	3500 visits/year (included in office visits)
------------------	---------	---

Clinical trials in inflammatory bowel disease have continued to flourish. We are participating in numerous international clinical trials under the direction of our research nurse, Stefania D'Aleo.

Rapid Access IBD Clinics: Monday to Thursday, 2-4 pm: 400 patients/year.

Hepatology clinic

Dr. N. Hilzenrat Monday to Friday 8-4 pm 4716 visits/year
(included in office visits)

Maria Stavrakis and Paul Plaisir are our research nurses in Hepatology. Activities include conduction of clinical trails in Hepatology as well as teaching and monitoring of patients undergoing anti-viral therapy for chronic hepatitis.

GI Service

In-patient activities revolve around the GI consulting service which is attended by our staff physician on a two week rotating schedule throughout the year. The volume of consultations is approximately 2400/year, the majority of which involve endoscopic procedures.

1. Research activities:

-Dr. Albert Cohen research interests focus on Crohn's disease, inflammatory bowel disease, ulcerative colitis and acid-related gastro-intestinal disorders.

-Dr Andrew Szilagyi's research interests include medical aspects of lactose and lactase as they pertain to lactose intolerance, diseases affected by dairy foods and epidemiology of lactose digestion. Related topics include irritable bowel syndrome and inflammatory bowel disease.

-Dr. Polymnia Galiatsatos is currently doing research on the impact of Lynch syndrome on career pursuits, professional development, and academic studies.

- Dr. Nir Hilzenrat major research interests are in the fields of liver diseases and gastroenterology: portal hypertension (basic sciences), viral hepatitis B & C - its treatment modalities and extrahepatic manifestations and complications (clinical studies) and colorectal cancer screening.

-Dr. Jonathan Wyse's research interests focus on the value of on-site cytopathology during endoscopic ultrasound and the study of biomarkers of irritable versus inflammatory bowel disease.

2. Teaching and learning (undergraduate and graduate):

Total clinical teaching hours

Gastroenterology Consult service	
Dr. S. Blum, Dr. A. Cohen,	300 hrs/yr.
Dr. G. Friedman, Dr. N. Hilzenrat	for each
Dr. A. Szilagyi, Dr. J. Wyse,	physician
Dr. P. Galiatsatos	

Post-graduate teaching hours

GI Pathology Conference	Wednesdays 8-9 am (alternate week)
Dr. Esther Lamoureux, Dr. A. Gologan	
Dr. Olga Aleynikova	

GI Radiology Conference Dr. M. Rosenbloom	Wednesdays 8-9 am (alternate week)
GI Journal Club, M&M rounds	Wednesdays 8-9 am, once/month
McGill interhospital GI rounds	Wednesdays 5-6 pm

MED 1:

McGill Gastrointestinal Physiology Small Group Tutor, Unit IV: Dr. A. Cohen, Dr. G. Friedman, Dr. N. Hilzenrat, Dr. P. Galiatsatos, Dr. J. Wyse and Dr. A. Szilagyi - total number of hours: 16/physician

Total Clinical Teaching hours:

Residents:	CTU: 80 hours	OPD: 800
Students:	CTU: 80 hours	OPD: 200

3. Involvement in the community:

Members of the Division continue to serve in committees and editorial boards and to participate in other high level academic activities at national and international levels.

4. Partnerships:

The division collaborates with gastroenterologists throughout Quebec in conjunction with the Whitehead Institute and the National Health Institute, Bethesda, MD for the identification of genes responsible for inflammatory bowel disease.

5. Milestones: New hires, promotions, and retirements: None to report.

6. Honours, awards, and prizes: None to report.

7. Fundraising: None to report.

SECTION I - DIVISION STATUS UPDATE

1. Mission and objectives of the Division

The main objectives of the division for the coming year are:
- expand the IBD Rapid Access Clinic and to potentially obtain a cross-appointment for another physician trained in interventional endoscopy to assist our division in this regard.

2. A nominative list of academic staff, their academic rank

Full-time (GFT) members:

Dr. Albert Cohen, Director of Division of Gastroenterology, Associate Professor, McGill University

Dr. Nir Hilzenrat, Gastroenterologist and Hepatologist, Associate Professor, McGill University

Dr. Gad Friedman, Gastroenterologist, Assistant Professor, McGill University

Dr. Polymnia Galiatsatos, Gastroenterologist, Assistant Professor, McGill University

Dr. Jonathan Wyse, Gastroenterologist, Assistant Professor, McGill University

Dr. Andrew Szilagyi, Gastroenterologist, Assistant Professor, McGill University

SECTION II - GRANTS, PUBLICATIONS, AND SERVICE OUTSIDE OF MCGILL

1. Grants and Awards

Dr. Albert Cohen

Protocol No. G1C13-01: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Proof of Concept Study of G1C-1001 in the Management of Visceral Pain in Subjects undergoing Sedation - Free Full colonoscopy. Sponsor: GICARE Pharm Inc.

MLN0002 in UC and Crohn's (C13008)

Extension Study An Open-Label Phase 3 Study: An Open-Label 3 Study to determine the long-term efficacy and safety of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease. Quintiles/CRO PRA Int)

Open-label Adalimumab S/C in Ulcerative Colitis, M10-223

Extension study of placebo controlled trial.

Multicenter International Trial, Site Principal Investigator, Sponsor: Abbott Laboratories

Quebec Genetic Consortium- Identification of the genes responsible for inflammatory bowel disease. This study represents collaboration between gastroenterologists throughout Quebec, involving all medical faculties in conjunction with the Whitehead Institute and the National Health Institute, Bethesda, MD.

Multicenter International trial, Site Principal Investigator, co-investigator: Dr. A. Szilagyi, Dr. G. Friedman, Dr. S. Blum, Dr. N. Hilzenrat, 2003 to present

Dr. Polymnia Galiatsatos

Impact of Lynch syndrome on career pursuits, professional development, and academic studies: JGH Department of Medicine Clinical Research Award 2014-2016

Dr. Nir Hilzenrat

The incidence of diabetes following interferon treatment in patients with HCV

Site principal investigator: Hilzenrat Nir, Co-investigator: Kader T, Funding: Jewish General Hospital, GI Research Group, 2004-date.

Chronic Hepatitis C infection Genotype 3: Do All Subjects Response Equally to the Current Therapy?

Site principal investigator: Hilzenrat Nir, Funding: SMBD- Jewish General Hospital, GI Research Group, 2009-date

The role of different biological systems in the etiology of interferon alpha induced depression. Principal Investigator: Marie-Josée Brouillette, Site principal investigator: Hilzenrat Nir, Co-investigator: Deschenes M, Funding: CHIR- Canadian Institutes of Health Research, 2008-date

Short term memory defect in HCV patients treated with Interferon, Site principal investigator: Hilzenrat Nir, Funding: SMBD- Jewish General Hospital, GI Research Group, 2011-date

Dr. Andrew Szilagyi

Differential effects of lactose on fecal microflora in adult Lactase Persistent and Lactase Non-Persistent healthy subjects (Danone Institute). This trial is registered at ClinicalTrials.gov ID NCT00599859

Epidemiological study of inflammatory bowel diseases and relationships to diet, vitamin D levels and genetics of lactase and NOD2, OCTN1/2.

Adaptability to fructose in fructose intolerant subjects: On going since January 2008.

Dr. Jonathan Wyse

The value of Botox-A in Acute Radiation Proctitis: JGH Department of Medicine Clinical Research Award 2013-2016

2. Publications

Dr. A. Cohen

U. Kopylov, W. Afif, A. Cohen, A. Bitton, G. Wild, T. Bessissow, J. Wyse, T. Al-Taweel, A. Szilagyi, E. Seidman. Subcutaneous Ustekinumab for the treatment of anti-8TNF resistant Crohn's disease: The McGill experience. *Journal of Crohn's and Colitis* (2014), <http://dx.doi.org/10.1016/j.crohns.2014.06.005>.

Brian G. Feagan, John W.D. McDonald, Remo Panaccione, Robert A Enns, Charles N. Bernstein, Terry P. Ponich, Raymond Bourdages, Donald G. MacIntosh, Chrystian Dallaire, Albert Cohen, Richard N. Fedorak, Pierre Paré, Alain Bitton, Fred Saibil, Frank Anderson, Allan donner, Cindy J. Wong, Guangyong zou, Margaret K. Vandervoort, Marybeth Hopkins, and Gordon R. Greenberg. Methotrexate in Combination with Infliximab is no more effective than Infliximab alone in Patients with Crohn's Disease. *Gastroenterology* 2014;146:681-688.

Dr. A. Szilagyi

Kopylov U, Eliakim-Raz N, Szilagyi A, Seidman E, Ben-Horin S, Katz L. Antiviral therapy in cytomegalovirus-positive ulcerative colitis: A systematic review and meta-analysis. *World J Gastroenterol* 2014, March 14;20(10): 2695- 2703.

Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, Bessissow T, Seidman E, Bitton A Vitamin B12 Deficiency in Inflammatory Bowel Disease: Prevalence, Risk Factors, Evaluation, and Management. *Inflamm Bowel Dis.* 2014 April 15. (Epub ahead of print).

Galiatsatos P, Wyse J, Szilagyi A. Accuracy of biopsies for *Helicobacter pylori* in the presence of intestinal metaplasia of the stomach. *Turk J Gastroenterol* 2014; 25: 19-23.

Szilagyi A, Leighton H, Burstein B, Xue X. Latitude, sunshine, and human lactase phenotype distributions may contribute to geographic patterns of modern disease: the inflammatory bowel disease model. *Clinical Epidemiology* 2014;6 183–198.

Kopylov U, Afif W, Cohen A, Bitton A, Wild G, Bessissow T, Wyse J, Al-Taweel T, Szilagyi A, Seidman E. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease: The McGill experience. *J Crohn's Colitis* 2014 July 1. pii: S1873 -9946 doi: 10.1016/j.crohns.2014.06.005.

Poster CDDW: Lu Y, Pehr K, Szilagyi A. Sweet's syndrome after 6-mercaptopurine exposure in Crohn's disease- recognizing 6-MP hypersensitivity. Poster A273 *Can J Gastroenterol Hepatol* 2014;28 Suppl A: 174-175A.

Dr. P. Galiatsatos

Galiatsatos P. Surveillance of Gastric Intestinal Metaplasia: Is It Warranted? *Journal of Gastroenterology and Hepatology Research.* 2014;3:1364-1366. Galiatsatos P, Szilagyi A. Author's Reply. *Turk J Gastroenterol* 2014;25:226-228

Galiatsatos P, Wyse J, Szilagyi A. Accuracy of biopsies for *Helicobacter pylori* in the presence of intestinal metaplasia of the stomach. *Turk J Gastroenterol* 2014;25:19-23

Galiatsatos P, Wyse J, Szilagyi A. Accuracy of biopsies for *Helicobacter pylori* in the presence of intestinal metaplasia of the stomach. *Can J Gastroenterol Hepatol* 2014;28(suppl A):148A-149A (abstract).

Dr. N. Hilzenrat

Cooper C, Shafran S, Greenbloom S, R Enns, Farley J, Hilzenrat N, Williams K, Elkashab M, Abadir N and Neuman M. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy. *Canadian Journal of Gastroenterology and Hepatology* 2014; 28: 35- 40.

SECTION III

1. Consulting activities: None reported

Respectfully submitted,

Albert Cohen, MD
Chief, Division of Gastroenterology